^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Excerpt:
This was a multi-institutional phase II study of selumetinib at 100 mg given orally twice per day to patients with advanced BC….Two patients with short-lived SD had KRAS mutations….Of the 25 samples successfully evaluated for KRAS G12/13X mutations, two were positive, which indicates the presence of G12S and G12D mutations.
DOI:
https://dx.doi.org/10.1200%2FJCO.2010.33.9473
Trial ID:
